WO2018174231A1 - 酵母におけるプロテアーゼの製造方法 - Google Patents
酵母におけるプロテアーゼの製造方法 Download PDFInfo
- Publication number
- WO2018174231A1 WO2018174231A1 PCT/JP2018/011631 JP2018011631W WO2018174231A1 WO 2018174231 A1 WO2018174231 A1 WO 2018174231A1 JP 2018011631 W JP2018011631 W JP 2018011631W WO 2018174231 A1 WO2018174231 A1 WO 2018174231A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protease
- pro
- amino acid
- acid sequence
- xaa
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Definitions
- the present invention relates to a method for producing a mold-derived trypsin-like protease in yeast, a mold-derived trypsin-like protease precursor, and the like.
- an appropriate host for the expression of the protein is used.
- hosts that can be used include animal cells such as CHO (Chinese Hamster Ovary) cells, insects and insect cells such as silkworms, animals such as chickens and cattle, and microorganisms such as Escherichia coli or yeast.
- yeast is capable of large-scale high-density culture with an inexpensive medium, and can produce proteins at low cost.
- secretory signal peptide or the like is used, secretory production into the culture solution is possible, and thus protein purification becomes easy.
- Trypsin is a serine protease produced in the pancreas of mammals and has protease activity that cleaves the C-terminal side of arginine residue or lysine residue, for the production of protein pharmaceuticals such as insulin or cell dispersion It is used.
- trypsin derived from mammals bovine, pig, human
- trypsin-like protease derived from mold and fish is also known.
- Patent Document 1 describes purification of trypsin-like protease from Fusarium oxysporum and cloning of the trypsin-like protease gene.
- Non-Patent Document 1 describes the production of trypsin-like protease in Fusarium oxysporum.
- Non-patent document 2 describes that trypsin derived from Streptomyces griseus is expressed by yeast (Pichia pastosis). Furthermore, Non-Patent Document 3 describes that porcine trypsin is expressed in yeast (Pichia pastosis).
- the present invention aims to provide a method for producing a mold-derived trypsin-like protease with high productivity in a method for producing a mold-derived trypsin-like protease using yeast as a host.
- a secretory signal sequence that functions in yeast a prosequence in which a mutation is introduced into a prosequence possessed by a trypsin-like protease derived from Fusarium oxysporum, and Fusarium -Fusarium oxysporum-derived trypsin-like protease can be produced with high productivity by expressing in yeast a gene encoding a fusion protein having the amino acid sequence of oxysporum-derived trypsin-like protease in this order from the N-terminal side to the C-terminal side As a result, the present invention has been completed.
- protease according to (1) wherein the protease and a protease precursor composed of the pro sequence and the amino acid sequence of the protease are secreted into the yeast culture supernatant at an activity ratio of 1: 1 or more.
- Method. (3) The method according to (1) or (2), wherein the protease precursor expressed in the culture supernatant is converted into a protease by the protease expressed in the culture supernatant.
- the trypsin-like protease derived from Fusarium oxysporum is any one of the following (a) to (c): (A) a protease comprising the amino acid sequence of SEQ ID NO: 67; (B) a protease comprising an amino acid sequence having a sequence identity of 90% or more with the amino acid sequence of SEQ ID NO: 67 and having a trypsin-like protease activity equivalent to the protease comprising the amino acid sequence of SEQ ID NO: 67; or (c) SEQ ID NO: A protease having a trypsin-like protease activity equivalent to the protease consisting of the amino acid sequence of SEQ ID NO: 67, comprising an amino acid sequence in which one or several amino acids are substituted, deleted, and / or added in the 67 amino acid sequence.
- the method according to any one of (1) to (4), wherein the secretory signal sequence that functions in yeast is a yeast MF sequence.
- the pro sequence is an amino acid sequence in which 1 to several amino acids are added, deleted or substituted to the amino acid sequence represented by Ala-Pro-Gln-Glu-Ile-Pro-Asn,
- Pro sequence is Ala- Pro-Gln-Glu-Ile-Pro-Xaa-Xbb, Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb, Xdd-Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb, Pro-Gln-Glu-Ile-Pro-Xaa-Xbb, Gln-Glu-Ile-Pro-Xaa-Xbb, Glu-Ile-Pro-Xaa-Xbb, Ile-Pro-Xaa-Xbb, Pro-Xaa-Xbb, or Xaa-Xbb (In the formula, Xaa represents an arbitrary amino acid residue, Xbb represents an Arg or Lys residue, Xcc represents an arbitrary amino acid residue, and Xdd represents an arbitrary amino acid residue)
- Xaa represents an arbitrary amino acid residue
- Xbb represents
- a protease precursor in which a prosequence having an arginine or lysine residue at the C-terminus is fused to the N-terminal side of the amino acid sequence of a Fusarium oxysporum-derived trypsin-like protease (I) When the protease precursor is expressed in the culture supernatant of yeast, the protease and the protease precursor composed of the pro sequence and the amino acid sequence of the protease are secreted at an activity ratio of 1: 1 or more. And (ii) the expressed protease allows the expressed protease precursor to be converted to a protease, Protease precursor.
- the protease precursor according to (8), wherein the trypsin-like protease derived from Fusarium oxysporum is any of the following (a) to (c): (A) a protease comprising the amino acid sequence of SEQ ID NO: 67; (B) a protease comprising an amino acid sequence having a sequence identity of 90% or more with the amino acid sequence of SEQ ID NO: 67 and having a trypsin-like protease activity equivalent to the protease comprising the amino acid sequence of SEQ ID NO: 67; or (c) SEQ ID NO: A protease having a trypsin-like protease activity equivalent to the protease consisting of the amino acid sequence of SEQ ID NO: 67, comprising an amino acid sequence in which one or several amino acids are substituted, deleted, and / or added in the 67 amino acid sequence.
- the pro sequence is an amino acid sequence in which one to several amino acids are added, deleted or substituted to the amino acid sequence represented by Ala-Pro-Gln-Glu-Ile-Pro-Asn,
- Pro sequence is Ala- Pro-Gln-Glu-Ile-Pro-Xaa-Xbb, Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb, Xdd-Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb, Pro-Gln-Glu-Ile-Pro-Xaa-Xbb, Gln-Glu-Ile-Pro-Xaa-Xbb, Glu-Ile-Pro-Xaa-Xbb, Ile-Pro-Xaa-Xbb, Pro-Xaa-Xbb, or Xaa-Xbb (In the formula, Xaa represents an arbitrary amino acid residue, Xbb represents an Arg or Lys residue, Xcc represents an arbitrary amino acid residue, and Xdd represents an arbitrary amino acid residue)
- the protease precursor according to any one of (8) to (10), which is
- the recombinant expression vector according to (12), wherein the trypsin-like protease derived from Fusarium oxysporum is any of the following (a) to (c): (A) a protease comprising the amino acid sequence of SEQ ID NO: 67; (B) a protease comprising an amino acid sequence having a sequence identity of 90% or more with the amino acid sequence of SEQ ID NO: 67 and having a trypsin-like protease activity equivalent to the protease comprising the amino acid sequence of SEQ ID NO: 67; or (c) SEQ ID NO: A protease having a trypsin-like protease activity equivalent to the protease consisting of the amino acid sequence of SEQ ID NO: 67, comprising an amino acid sequence in which one or several amino acids are substituted, deleted, and / or added in the 67 amino acid sequence.
- a prosequence is an amino acid sequence in which one to several amino acids are added, deleted or substituted to the amino acid sequence represented by Ala-Pro-Gln-Glu-Ile-Pro-Asn,
- the prosequence is Ala- Pro-Gln-Glu-Ile-Pro-Xaa-Xbb, Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb, Xdd-Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb, Pro-Gln-Glu-Ile-Pro-Xaa-Xbb, Gln-Glu-Ile-Pro-Xaa-Xbb, Glu-Ile-Pro-Xaa-Xbb, Ile-Pro-Xaa-Xbb, Pro-Xaa-Xbb, or Xaa-Xbb (In the formula, Xaa represents an arbitrary amino acid residue, Xbb represents an Arg or Lys residue, Xcc represents an arbitrary amino acid residue, and Xdd represents an arbitrary amino acid residue)
- the recombinant expression vector according to any one of (12)
- a yeast culture-derived protease composition comprising a Fusarium oxysporum-derived trypsin-like protease expressed in yeast.
- mold-derived trypsin-like protease can be produced in yeast with high productivity.
- FIG. 1 shows the results of SDS-PAGE analysis of the culture supernatant obtained in Comparative Example 3.
- Lane 1 shows MF-prosequence-protease and lane 2 shows MF-protease.
- FIG. 2 shows the results of SDS-PAGE analysis of the samples before and after the autolysis treatment for the culture supernatant obtained in Example 6.
- M is a marker
- lane 1 is the culture supernatant before the conversion reaction (MF-APQEIPNK-trypsin)
- lane 2 is the result after the self-digestion reaction.
- protease in yeast a secretory signal sequence that functions in yeast and a pro sequence (more specifically, a pro sequence of a trypsin-like protease derived from Fusarium oxysporum are introduced with a mutation and an arginine or lysine residue at the C-terminal). And a gene encoding a fusion protein having, in this order, from the N-terminal side to the C-terminal side the amino acid sequence of Fusarium oxysporum-derived trypsin-like protease, the protease is produced in yeast.
- the above fusion protein is used in yeast by using a recombinant expression vector having a DNA encoding a secretory signal sequence that functions in yeast, the above pro sequence, and the amino acid sequence of a trypsin-like protease derived from Fusarium oxysporum.
- a protease precursor composed of a pro sequence and an amino acid sequence of a protease and a protease are first expressed.
- the protease precursor expressed in the culture supernatant was converted into protease by the protease expressed in the culture supernatant. According to the above mechanism, in the present invention, it has become possible to efficiently produce (manufacture) a Fusarium oxysporum-derived trypsin-like protease having a desired protease activity in yeast.
- the expression ratio of the protease and the protease precursor in the yeast culture supernatant is not particularly limited, but is preferably secreted at an activity ratio of 1: 1 or more, more preferably 1: It is secreted at an activity ratio of 10 or more, more preferably at an activity ratio of 1: 100 or more.
- the activity ratio here refers to the amount of protease activity in the culture supernatant (the amount of protease activity in the culture supernatant before the conversion from the protease precursor to protease by self-digestion after cultivation) as the expression level of the protease, It shows the expression level ratio when the activity level obtained by subtracting the protease activity level in the culture supernatant from the protease activity level after self-digestion is used as the expression level of the protease precursor.
- the trypsin-like protease derived from Fusarium oxysporum means a trypsin-like protease expressed by Fusarium oxysporum or a variant thereof.
- the trypsin-like protease expressed by Zalium oxysporum is a protease consisting of the amino acid sequence of SEQ ID NO: 67.
- a modified trypsin-like protease expressed by Fusarium oxysporum (B) consisting of an amino acid sequence having a sequence identity of 90% or more (preferably 95% or more, more preferably 98% or more) with the amino acid sequence of SEQ ID NO: 67, which is equivalent to the protease comprising the amino acid sequence of SEQ ID NO: 67 A protease having trypsin-like protease activity; or (c) 1 or several (preferably 1 to 10, more preferably 1 to 5, more preferably 1 to 3) amino acids in the amino acid sequence of SEQ ID NO: 67 A protease comprising a substituted, deleted and / or added amino acid sequence and having a trypsin-like protease activity equivalent to a protease comprising the amino acid sequence of SEQ ID NO: 67. May be expressed. Examples include mutants in which the R104 residue (Arg residue which is the 104th amino acid residue) of SEQ ID NO: 67 described in
- sequence identity of amino acid sequences is determined by the algorithm BLAST [Pro. Natl. Acad. Sci. USA, 90, 5873 (1993)] and FASTA [Methods Enzymol. , 183, 63 (1990)].
- amino acid to be substituted is preferably an amino acid having similar properties to the amino acid before substitution (cognate amino acid).
- amino acids within the same group of the following groups are considered homologous amino acids: (Group 1: neutral nonpolar amino acids) Gly, Ala, Val, Leu, Ile, Met, Cys, Pro, Phe; (Group 2: neutral polar amino acids) Ser, Thr, Gln, Asn, Trp, Tyr; (Group 3: acidic amino acids) Glu, Asp; (Group 4: basic amino acids) His, Lys, Arg:
- a DNA encoding the above-described modified trypsin-like protease can be obtained by a conventional method known to those skilled in the art, such as site-directed mutagenesis.
- a commercially available mutagenesis kit for example, Mutant- K, Mutant-G, LA PCR in vitro Mutagenesis series kit (manufactured by TAKARA) can also be used.
- the secretory signal sequence that functions in yeast used in the present invention is a sequence that directs the transport and localization of the protein biosynthesized in the cytoplasm to the endoplasmic reticulum, and is present at the N-terminus of the protein. It is a peptide having a function of secreting the expressed protein outside the host cell yeast.
- the secretory signal sequence is usually removed by degradation by a signal peptidase when the secreted protein is secreted from the inside of the cell through the cell membrane to the outside of the cell.
- the secretion signal sequence that functions in yeast used in the present invention may be any sequence that functions in yeast, and may be either a secretion signal sequence derived from yeast or a secretion signal sequence derived from organisms other than yeast. Preferably, it is a secretion signal sequence derived from yeast.
- secretory signal sequences that function in yeast include mating Factor ⁇ (MF ⁇ ) prepro signal sequence (MF sequence) of yeast (Saccharomyces cerevisiae, etc.), Ogata Air polymorpha and Komagataella pastoris acid phosphatase (PHO1), and Saccharomyces.
- MF ⁇ mating Factor ⁇
- MF sequence prepro signal sequence
- SUC2 S. cerevisiae invertase
- Saccharomyces cerevisiae PLB1 can be mentioned, but is not particularly limited.
- the pro sequence used in the present invention is obtained by introducing a mutation into the pro sequence of Fusarium oxysporum-derived trypsin-like protease, and preferably has an arginine or lysine residue at the C-terminus thereof. .
- Ala-Pro-Gln-Glu-Ile-Pro-Asn can be mentioned as the amino acid sequence of the pro-sequence of Fusarium oxysporum-derived trypsin-like protease. Therefore, the pro sequence used in the present invention is 1 to several (preferably 1 to 7, more preferably 1 to 1) of the amino acid sequence represented by Ala-Pro-Gln-Glu-Ile-Pro-Asn. 6 (for example, 1, 2, 3, 4, 5 or 6) amino acid sequences added, deleted or substituted, and having an arginine or lysine residue at the C-terminus Can be mentioned.
- the pro-sequence used in the present invention is an amino acid sequence that is cleaved at the C-terminus in yeast to produce a protease from a protease precursor.
- the amino acid to be substituted is preferably an amino acid having a property similar to that of the amino acid before substitution (cognate amino acid).
- the homologous amino acid is as described above in the present specification.
- pro sequences include Ala- Pro-Gln-Glu-Ile-Pro-Xaa-Xbb, Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb, Xdd-Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb, Pro-Gln-Glu-Ile-Pro-Xaa-Xbb, Gln-Glu-Ile-Pro-Xaa-Xbb, Glu-Ile-Pro-Xaa-Xbb, Ile-Pro-Xaa-Xbb, Pro-Xaa-Xbb, or Xaa-Xbb (In the formula, Xaa represents an arbitrary amino acid residue, Xbb represents an Arg or Lys residue, Xcc represents an arbitrary amino acid residue, and Xdd represents an arbitrary amino acid residue) The amino acid sequence shown by either of these can be mentioned.
- pro sequence 1 to several (preferably 1 to 7, more preferably 1 to the amino acid sequence represented by Ala- Pro-Gln-Glu-Ile-Pro-Asn-Arg)
- Amino acid sequence substituted with 6 (for example, 1, 2, 3, 4, 5, or 6) amino acids, or Ala- Pro-Gln-Glu-Ile-Pro-Asn-Lys 1 to several (preferably 1 to 7, more preferably 1 to 6, for example 1, 2, 3, 4, 5, or 6) amino acids are substituted in the amino acid sequence.
- Amino acid sequences can be mentioned.
- Xaa, Xbb and Xcc each independently represent any amino acid residue, specifically, Asp, Gly, Ala, Val, Leu, Ile, Cys, Met, Ser, Thr, Tyr, Phe, Trp, Pro, Glu, Asn, Gln, Lys, Arg, or His is represented.
- Asp, Gly, Ala, Val, Leu, Ile, Cys, Met, Ser, Thr, Tyr, Phe, Trp, Pro, Glu, Asn, Gln, Lys, Arg, and His are aspartic acid residues, Glycine residue, alanine residue, valine residue, leucine residue, isorocicin residue, cysteine residue, methionine residue, serine residue, threonine residue, tyrosine residue, phenylalanine residue, tryptophan residue, proline residue
- Xaa is preferably Asn, Gly, Asp, Ser, Arg, Thr, Glu, Val, His, Ala, Tyr, Ile, Gln, or Met.
- Xcc and Xdd are preferably neutral amino acid residues (Gly, Ala, Val, Leu, Ile, Cys, Met, Ser, Thr, Tyr, Phe, Trp, Pro, Asn, Gln), more preferably fat Group amino acid residues (Gly, Ala, Val, Leu, Ile), more preferably Ala.
- a secretory signal sequence that functions in yeast a prosequence of Fusarium oxysporum-derived trypsin-like protease introduced with mutations, a prosequence having an arginine or lysine residue at the C-terminus, and Fusarium oxysporum-derived trypsin-like Fusarium oxysporum-derived trypsin-like protease is expressed and secreted in yeast using a recombinant expression vector having a DNA encoding a fusion protein having the amino acid sequence of the protease in this order from the N-terminal side to the C-terminal side.
- the recombinant expression vector in the present invention means a nucleic acid molecule having a function of expressing a gene in an expression cassette incorporated in a recombinant expression vector in a host cell after transformation.
- the recombinant expression vector may have an integration homologous region, a selection marker gene such as an auxotrophic complementary gene or a drug resistance gene, an autonomously replicating sequence, and the like.
- the vector after being transformed into the host may be incorporated in the chromosome of the transformant or may exist as an autonomously replicating type.
- the expression vector may be a plasmid vector or an artificial chromosome.
- a plasmid vector is preferable in that the preparation of the vector is easy and the transformation of yeast cells is easy.
- the plasmid include plasmids derived from E. coli (eg, pBR322, pBR325, pUC118, pUC119, pUC119, pUC18, pUC19, pBluescript, etc.), plasmids derived from Bacillus subtilis (eg, pUB110, pTP5, etc.), yeast-derived plasmids (eg, YEp systems such as YEp13). , YCp series such as YCp50), and the like.
- the “expression cassette” in the present invention is composed of a promoter and a target protein gene to be expressed, and may contain a terminator.
- a terminator for example, it can be constructed on a plasmid such as pUC, or can be prepared by a PCR method. it can.
- AOX1 promoter As the promoter, AOX1 promoter, AOX2 promoter, CAT promoter, DHAS promoter, FDH promoter, FMD promoter, GAP promoter, MOX promoter, TEF promoter, LEU2 promoter, URA3 promoter, ADE promoter, ADH1 promoter, PGK1 promoter, etc. should be used. However, it is not particularly limited.
- AOX1 terminator As the terminator, AOX1 terminator, GAP terminator, ADH1 terminator and the like can be used, but are not particularly limited.
- the integration homologous region in the present invention refers to a region in which the recombinant vector of the present invention is integrated by homologous recombination on the chromosome of the host cell after transformation.
- a part of the chromosome of the host cell can be arbitrarily used, but an auxotrophic complementary gene, a promoter or a terminator in an expression cassette, etc. can also be used.
- the auxotrophic complementary gene in the present invention is not particularly limited as long as it is a gene that complements auxotrophy such as amino acids and nucleic acids of host cells.
- Specific examples include the URA3 gene, the LEU2 gene, the ADE1 gene, the HIS4 gene, etc., which can be selected by restoring the prototrophic phenotype in uracil, leucine, adenine, and histidine auxotrophic strains, respectively. .
- the selection mer gene such as a drug resistance gene in the present invention is not particularly limited as long as it is a gene imparting drug resistance not possessed by a host cell. Specific examples include a G418 resistance gene, a zeocin resistance gene, a hygromycin resistance gene, and the like, which can be selected based on resistance on a medium containing G418, zeocin, and hygromycin, respectively.
- the auxotrophic selection marker used when preparing the yeast host cannot be used when the selection marker is not destroyed. In this case, the selection marker may be recovered, and methods known to those skilled in the art can be used.
- the autonomously replicating sequence in the present invention refers to a sequence that acts as a replication origin of the recombinant vector of the present invention and enables autonomous replication in a host cell.
- a transformed yeast having the above-described recombinant expression vector of the present invention is provided.
- the type of yeast is not particularly limited, but methanol-assimilating yeast is more preferable, and methanol-assimilating yeast belonging to the genus Ogataea and Komagataella is more preferable.
- methanol-assimilating yeasts belonging to the genus Ogataea Ogataea polymorpha and Ogataea minuta are preferred, and in the methanol-assimilating yeast belonging to the genus Komagataera, Komagatastaella papori is preferred. .
- the method for introducing the recombinant expression vector of the present invention into yeast is not particularly limited as long as it can introduce DNA into yeast.
- transfection methods such as lithium method, spheroplast method, protoplast method, and microinjection method
- a method for transformation into a chromosome or insertion type yeast using a vector such as a YIp system or a DNA sequence homologous to an arbitrary region in a chromosome can also be used.
- the transformed yeast in the present invention means a yeast introduced with the recombinant vector of the present invention.
- the transformed yeast of the present invention can be selectively obtained using the phenotype obtained by the auxotrophic complementary gene or drug resistance gene contained in the recombinant vector as an index.
- telomere length is determined by telomere length and telomere length.
- telomere length is determined by telomere length and telomere length.
- amplification product is electrophoresed (agarose gel, polyacrylamide gel or capillary), and ethidium bromide, SYBR Green solution, etc. Transformation can be confirmed by staining and detecting the amplified product.
- amplification products can be detected by performing PCR using primers previously labeled with a fluorescent dye or the like.
- Any medium can be used as a medium for cultivating the transformed yeast as long as it contains a nutrient source that the yeast assimilate.
- the nutrient source include sugars such as glucose, sucrose, and maltose, lactic acid, acetic acid, and citric acid.
- Carbon sources such as organic acids such as propionic acid, alcohols such as methanol, ethanol and glycerol, hydrocarbons such as paraffin, oils and fats such as soybean oil and rapeseed oil, or mixtures thereof, ammonium sulfate, ammonium phosphate, urea
- a normal medium in which nitrogen sources such as yeast extract, meat extract, peptone, corn steep liquor, and other nutrient sources such as other inorganic salts and vitamins are appropriately mixed and blended can be used.
- nitrogen sources such as yeast extract, meat extract, peptone, corn steep liquor, and other nutrient sources such as other inorganic salts and vitamins are appropriately mixed and blended can be used.
- the culture method can be any of batch culture, continuous culture, or dome culture.
- Cultivation can usually be carried out under general conditions, for example, pH 2.5 to 10.0, preferably pH 4.0 to 8.0, temperature 10 ° C. to 48 ° C., preferably 20 ° C. to 42 ° C., more preferably It can be carried out by aerobically culturing at 25 ° C. to 37 ° C. for 10 hours to 10 days.
- protease precursor in which a prosequence having an arginine or lysine residue at the C-terminus is fused to the N-terminal side of the amino acid sequence of a trypsin-like protease derived from Fusarium oxysporum.
- the protease precursor of the present invention comprises (I) when the protease precursor is expressed in the culture supernatant of yeast, the protease and the protease precursor are secreted at a ratio of 1: 1 or more; and (ii) the expressed protease
- the expressed protease precursor can be converted to a protease; It has the characteristics.
- the protease precursor of the present invention can be produced by transformed yeast by culturing the above-described transformed yeast. Therefore, the protease precursor of the present invention can be obtained by secretory production in which the transformed yeast of the present invention is cultured and the protease precursor of the present invention is accumulated in the culture supernatant.
- the secretory production in the present invention refers to liquid culture of transformed yeast and accumulation of a protease precursor and a protease not in the cells but in the culture supernatant.
- a yeast culture-derived protease composition comprising a Fusarium oxysporum derived trypsin-like protease expressed in yeast.
- the composition of the present invention is a yeast culture-derived protease composition and may contain a yeast culture-derived component.
- the trypsin-like protease derived from Fusarium oxysporum in the present invention is expressed in yeast and may be subjected to translation word modification in yeast.
- the Fusarium oxysporum-derived trypsin-like protease is preferably any of the following (a) to (c) as described above in the present specification.
- A a protease comprising the amino acid sequence of SEQ ID NO: 67;
- B consisting of an amino acid sequence having a sequence identity of 90% or more (preferably 95% or more, more preferably 98% or more) with the amino acid sequence of SEQ ID NO: 67, which is equivalent to the protease comprising the amino acid sequence of SEQ ID NO: 67 A protease having trypsin-like protease activity; or (c) 1 or several (preferably 1 to 10, more preferably 1 to 5, more preferably 1 to 3) amino acids in the amino acid sequence of SEQ ID NO: 67 A protease comprising a substituted, deleted and / or added amino acid sequence and having a trypsin-like protease activity equivalent to a protease comprising the amino acid sequence of SEQ ID NO: 67
- the culture supernatant or culture after culturing the transformed yeast of the present invention contains Fusarium oxysporum-derived trypsin-like protease and its precursor (protease precursor).
- protease precursor it is preferable to convert the protease precursor into a trypsin-like protease derived from Fusarium oxysporum by performing autolysis in the culture supernatant or culture.
- Self-digestion can be performed by adjusting the culture supernatant or culture to a reaction solution under conditions suitable for the self-digestion reaction and incubating the resulting reaction solution.
- the self-digestion reaction is preferably performed under the conditions of pH 6 to 10, more preferably pH 7 to 9, in the presence of Mg 2+ ions, and a temperature of 0 ° C. to 40 ° C., more preferably a temperature of 4 ° C. to 20 ° C. it can.
- Isolation and purification of a trypsin-like protease derived from Fusarium oxysporum can be carried out by appropriately combining known protein purification methods. For example, after transforming yeast is cultured in a suitable medium, the cells are removed from the culture supernatant by centrifugation of the culture solution or filtration. Then, the obtained culture supernatant can be used for autolysis as desired.
- Fusarium oxysporum-derived trypsin-like protease can be recovered by techniques such as hydrophobic chromatography, affinity chromatography, reverse phase chromatography, and ultrafiltration.
- the Fusarium oxysporum-derived trypsin-like protease recovered as described above can be used as it is, but may be used after various preparation treatments.
- the protease composition of the present invention can be used as a proteolytic enzyme.
- the pH and temperature of the enzyme reaction may be within a range in which the trypsin-like protease in the protease composition of the present invention can exert trypsin activity.
- the reaction can be performed under conditions of pH 6 to 12, more preferably pH 7 to 10, temperature 4 ° C. to 40 ° C., more preferably temperature 20 ° C. to 37 ° C.
- yeast culture-derived protease composition of the present invention is not particularly limited.
- the yeast culture-derived protease composition of the present invention includes, for example, detergents (detergents for medical equipment, dishwasher detergents, laundry detergents, etc.), feed processing, food processing (fish oil processing, meat processing, etc.), fiber It can be used for processing, wool processing, leather processing, contact lens cleaning, piping cleaning, medicine, etc., and may be blended in bathing agents and hair removal agents.
- the plasmid used for yeast transformation is the constructed vector expressed by E. coli E. coli. This was introduced into E. coli DH5 ⁇ competent cell (manufactured by Takara Bio Inc.), and the resulting transformant was cultured and amplified. Preparation of the plasmid from the plasmid-carrying strain was performed using QIAprep spin miniprep kit (manufactured by QIAGEN).
- the AOX1 promoter (SEQ ID NO: 2), AOX1 terminator (SEQ ID NO: 3), and HIS4 gene (SEQ ID NO: 4) used in the construction of the vector are the chromosomal DNA of Komagataela pastoris ATCC76273 (base sequence is EMBL (The European Molecular Biology Laboratory). ) ACCESSION No. FR839628 to FR839631) Prepared by PCR using the mixture as a template.
- the wild type protease precursor gene (SEQ ID NO: 5) provided with the mating factor ⁇ prepro signal sequence (MF sequence) used in the construction of the vector was prepared based on the public sequence information.
- MF sequence mating factor ⁇ prepro signal sequence
- PCR Prime STAR HS DNA Polymerase (manufactured by Takara Bio Inc.) or the like was used, and the reaction conditions were as described in the attached manual.
- Chromosomal DNA was prepared using Gen Toru-kun TM (manufactured by Takara Bio Inc.) from Komagataela pastoris ATCC 76273 strain under the conditions described therein.
- Comparative Example 1 Construction of a secretory expression vector for a wild-type protease precursor A gene fragment (SEQ ID NO: 6) having a multiple cloning site of HindIII-BamHI-BglII-XbaI-EcoRI was fully synthesized, and this was synthesized with pUC19 (manufactured by Takara Bio Inc.). PUC-1 was constructed by inserting it between the HindIII-EcoRI sites of Code No. 3219).
- a nucleic acid fragment added with a BamHI recognition sequence on both sides of the AOX1 promoter was prepared by PCR using primers 1 (SEQ ID NO: 7) and 2 (SEQ ID NO: 8), and inserted into the BamHI site of pUC-1 after BamHI treatment.
- primers 1 SEQ ID NO: 7
- 2 SEQ ID NO: 8
- nucleic acid fragment added with an XbaI recognition sequence on both sides of the AOX1 terminator was prepared by PCR using primers 3 (SEQ ID NO: 9) and 4 (SEQ ID NO: 10). After XbaI treatment, the nucleic acid fragment was added to the XbaI site of pUC-Paox. Inserted to construct pUC-PaoxTaox.
- a nucleic acid fragment having EcoRI recognition sequences added to both sides of the HIS4 gene was prepared by PCR using primers 5 (SEQ ID NO: 11) and 6 (SEQ ID NO: 12). After EcoRI treatment, the nucleic acid fragment was added to the EcoRI site of pUC-PaoxTaox. Inserted to construct pUC-PaoxTaoxHIS4.
- a nucleic acid fragment having a BglII recognition sequence added to both sides of the protease precursor gene to which the MF sequence was added was prepared by PCR using primers 7 (SEQ ID NO: 13) and 8 (SEQ ID NO: 14), and treated with BglII. Later, it was inserted into the BglII site of pUC-PaoxTaoxHIS4 to construct pUC-PaoxTPTaoxHIS4. This pUC-PaoxTPTaoxHIS4 is designed so that the wild-type protease precursor gene is secreted and expressed under the control of the AOX1 promoter.
- Comparative Example 2 Acquisition of transformed yeast Using the wild-type protease precursor expression vector constructed in Comparative Example 1, Komagataela pastoris was transformed as follows. A histidine-requiring strain derived from Komagataela pastoris ATCC76273 strain was inoculated into 3 ml of YPD medium (1% yeast extract bacto (manufactured by Difco), 2% polypeptone (manufactured by Nippon Pharmaceutical Co., Ltd.), 2% glucose) overnight at 30 ° C. A preculture was obtained by shaking culture.
- YPD medium 1% yeast extract bacto (manufactured by Difco), 2% polypeptone (manufactured by Nippon Pharmaceutical Co., Ltd.), 2% glucose
- the obtained preculture solution (500 ⁇ l) was inoculated into 50 ml of YPD medium, shake-cultured until OD600 was 1 to 1.5, collected (3000 ⁇ g, 10 minutes, 20 ° C.), and 250 ⁇ l of 1M DTT ( It was resuspended in 10 ml of 50 mM potassium phosphate buffer, pH 7.5 containing 25 mM final concentration).
- This suspension was incubated at 30 ° C. for 15 minutes, and then collected (3000 ⁇ g, 10 minutes, 20 ° C.), and ice-cooled 50 ml of STM buffer (270 mM sucrose, 10 mM Tris-HCl, 1 mM magnesium chloride, pH 7) 5). The washings were collected (3000 ⁇ g, 10 minutes, 4 ° C.), washed again with 25 ml of STM buffer, and then collected (3000 ⁇ g, 10 minutes, 4 ° C.). Finally, it was suspended in 250 ⁇ l of ice-cold STM buffer, which was used as a competent cell solution.
- STM buffer 270 mM sucrose, 10 mM Tris-HCl, 1 mM magnesium chloride, pH 7
- Escherichia coli was transformed with the wild-type protease precursor expression vector pUC-PaoxTPTaoxHIS4 constructed in Comparative Example 1, and the resulting transformant was treated with 2 ml of ampicillin-containing 2YT medium (1.6% tryptone bacto (manufactured by Difco)). 1% yeast extract bacto (manufactured by Difco), 0.5% sodium chloride, 0.01% ampicillin sodium (manufactured by Wako Pure Chemical Industries, Ltd.)), and QIAprep spin miniprep kit (QIAGEN) Was used to obtain pUC-PaoxTPTaoxHIS4. This plasmid was treated with SalI to prepare a linear vector cleaved with a SalI recognition sequence in the HIS4 gene.
- the cells were resuspended in an appropriate amount of YNB medium and then applied to a YNB selective agar plate (0.67% yeast nitrogen base Without Amino Acid (manufactured by Difco), 1.5% agarose, 2% glucose), 30 A strain that grows in a static culture at 3 ° C. for 3 days was selected, and a wild-type protease precursor-expressing yeast was obtained.
- YNB selective agar plate 0.67% yeast nitrogen base Without Amino Acid (manufactured by Difco), 1.5% agarose, 2% glucose
- Comparative Example 3 Culture of transformed yeast The wild-type protease precursor-expressing yeast obtained in Comparative Example 2 was treated with 2 ml of BMGY medium (1% yeast extract bacto (Difco), 2% polypeptone (Nippon Pharmaceutical Co., Ltd.), 0.34% yeast nitrogen base Without Amino Acid and Ammonium Sulfate (manufactured by Difco), 1% Ammonium Sulfate, 0.4 mg / l Biotin, 100 mM potassium phosphate (pH 6.0), 1% glycerol, 1% glycerol After inoculation and shaking culture at 30 ° C. for 48 hours, the culture supernatant was collected by centrifugation (12000 rpm, 5 minutes, 4 ° C.).
- BMGY medium 1% yeast extract bacto (Difco), 2% polypeptone (Nippon Pharmaceutical Co., Ltd.), 0.34% yeast nitrogen base Without Amino Acid and Ammonium Sulfate (manufactured by
- Comparative Example 4 SDS-PAGE of culture supernatant SDS-PAGE analysis of the culture supernatant obtained in Comparative Example 3 was performed. Mix 12 ⁇ l of culture supernatant and 3 ⁇ l of 5 ⁇ sample buffer (0.25 M Tris-HCl (pH 6.8), 50% Glycerol, 6.7% SDS, 0.01% BPB) and treat at 95 ° C. for 8 min. Did. This sample was subjected to SDS-PAGE electrophoresis using an e-PAGE gel (ER15L, manufactured by ATTO) together with a molecular weight marker (Precision Plus Protein ' TM Dual Color Standards, manufactured by Bio-Rad).
- sample buffer (0.25 M Tris-HCl (pH 6.8), 50% Glycerol, 6.7% SDS, 0.01% BPB) and treat at 95 ° C. for 8 min. Did.
- This sample was subjected to SDS-PAGE electrophoresis using an e-PAGE gel (ER15L, manufactured by
- Comparative Example 5 Conversion of protease precursor by self-digestion
- the protease precursor present in the culture supernatant was converted to the active form by self-digestion as follows. 500 ⁇ l of the culture supernatant was replaced with an activity measurement buffer (10 mM TrisHCl (pH 8.0), 10 mM MgCl 2) using Amicon Ultracel-3K (manufactured by Merck Millipore). Thereafter, using the same buffer, the liquid volume was adjusted to 500 ⁇ l and incubated at 15 ° C. for 24-48 hours.
- an activity measurement buffer 10 mM TrisHCl (pH 8.0), 10 mM MgCl 2
- Amicon Ultracel-3K manufactured by Merck Millipore
- the amount of enzyme that generates 1 ⁇ mol of p-nitroaniline in 1 min was defined as 1 unit.
- Protease activity in the culture supernatant obtained in Comparative Example 3 and the solution after self-digestion obtained in Comparative Example 5 was measured by the above method, but no activity was detected (Table 1).
- Comparative Example 7 Construction of protease expression vector A protease gene was prepared by PCR using a synthetic gene of a wild-type protease precursor gene to which an MF sequence was added as a template. PCR was performed using Primer 7 and Primer 9 (SEQ ID NO: 15), Primer 10 (SEQ ID NO: 16) and Primer 8, and after amplification of each PCR was mixed, PCR was performed with Primer 7 and Primer 8. A protease gene with an MF sequence was prepared.
- protease gene prepared above was treated with BglII and inserted into the BglII site of pUC-PaoxTaoxHIS4 prepared in Comparative Example 1 to construct a protease gene expression vector to which an MF sequence was added.
- Comparative Example 8 Protease Production of Protease Using the vector constructed in Comparative Example 7, the treatments of Comparative Examples 2 to 6 were performed to evaluate the secretory production of protease in Pichia yeast. As a result, although a small amount of protease activity was observed in the culture supernatant, no protease band was observed on PAGE (FIG. 1, lane 2, Table 1). This result indicates that it is difficult to secrete the prosthesis with Pichia yeast.
- Comparative Example 9 Construction of Mutant Protease Precursor Expression Vector A mutant protease precursor gene having a porcine trypsin-derived prosequence was prepared by PCR using a synthetic gene of a wild-type protease precursor gene to which an MF sequence was added as a template. PCR was performed using Primer 7 and Primer 11 (SEQ ID NO: 17), Primer 12 (SEQ ID NO: 18) and Primer 8, and after amplification fragments of each PCR were mixed, PCR was performed with Primer 7 and Primer 8. A mutant protease precursor gene to which an MF sequence was added was prepared.
- protease gene prepared above was treated with BglII and inserted into the BglII site of pUC-PaoxTaoxHIS4 prepared in Comparative Example 1 to construct a mutant protease precursor gene expression vector to which an MF sequence was added.
- Comparative Example 10 Secretory Production of Mutant Protease Precursor Using the vector constructed in Comparative Example 9, the treatments of Comparative Examples 2 to 6 were performed to evaluate the secretory production of the mutant protease precursor in Pichia yeast. As a result, no protease activity was observed in the culture supernatant (Table 1), and a band different from the size estimated from the amino acid sequence was observed on PAGE. This result shows that even if the prosequence of porcine trypsin, which has been reported to be converted from a precursor to an active form by autolysis, does not function well with this protease.
- Example 1 Construction of mutant protease precursor expression vector 1
- An N7NR mutant precursor gene was prepared by PCR using a synthetic gene of a wild-type protease precursor gene to which an MF sequence was added as a template. PCR was performed using primer 7 and primer 13 (SEQ ID NO: 19), primer 14 (SEQ ID NO: 20) and primer 8, and after mixing the amplified fragments of each PCR, PCR was performed using primer 7 and primer 8. A N7NR mutant precursor gene having an MF sequence was prepared.
- mutant protease precursor gene prepared above was treated with BglII and inserted into the BglII site of pUC-PaoxTaoxHIS4 prepared in Comparative Example 1 to construct various mutant protease precursor gene expression vectors with MF sequences.
- This mutant precursor has a mutation in which an R residue is inserted between residues corresponding to N7 and I8 of the wild type precursor.
- Example 2 Construction 2 of a mutant protease precursor expression vector An N7NK mutant precursor gene was prepared by PCR using a synthetic gene of a wild-type protease precursor gene to which an MF sequence was added as a template. PCR was performed using primer 7 and primer 15 (SEQ ID NO: 21), primer 16 (SEQ ID NO: 22), and primer 8, and after amplification fragments of each PCR were mixed, PCR was performed with primer 7 and primer 8. The N24NK mutation precursor gene to which the MF sequence was assigned was prepared.
- the mutant protease precursor gene prepared above was treated with BglII and inserted into the BglII site of pUC-PaoxTaoxHIS4 prepared in Comparative Example 1 to construct various mutant protease precursor gene expression vectors to which MF sequences were added. .
- This mutant precursor has a mutation in which a K residue is inserted between residues corresponding to N7 and I8 of the wild type precursor.
- Example 3 Construction of a mutant protease precursor expression vector 3 Using the expression vector of the N7NR mutation precursor gene constructed in Example 1 as a template, PCR was performed using the combinations of primers (1stPCR-1, 1stPCR-2) shown in Table 2 below. PCR was carried out with primers 7 and 8 using a mixture of fragments as a template to prepare various mutant protease precursor genes with MF sequences.
- the mutant protease precursor gene prepared above was treated with BglII and inserted into the BglII site of pUC-PaoxTaoxHIS4 prepared in Comparative Example 1 to construct various mutant protease precursor gene expression vectors to which MF sequences were added. .
- These mutant precursors have mutations in which an R residue is inserted between residues corresponding to wild-type precursors N7 and I8, and a residue corresponding to N7 is substituted with another amino acid residue.
- Example 4 Construction of mutant protease precursor expression vector 4 Using the expression vector of the N7NK mutant precursor gene constructed in Example 2 as a template, PCR was performed using the combinations of primers (1stPCR-1, 1stPCR-2) shown in Table 3 below. PCR was carried out with primers 7 and 8 using a mixture of fragments as a template to prepare various mutant protease precursor genes with MF sequences. The mutant protease precursor gene prepared above was treated with BglII and inserted into the BglII site of pUC-PaoxTaoxHIS4 prepared in Comparative Example 1 to construct various mutant protease precursor gene expression vectors with MF sequences. .
- mutation precursors are mutations in which a K residue is inserted between residues corresponding to wild-type precursors N7 and I8, and a residue corresponding to N7 is replaced with another amino acid residue.
- Example 5 Secretory production of mutant protease precursor 1 Using the various mutant protease precursor gene expression vectors obtained in Examples 1 and 3, the treatments described in Comparative Examples 2 to 6 were performed, and secretion production of mutant protease precursors in Pichia yeast was evaluated. As a result, protease activity was observed in the culture supernatant (Table 4), and a precursor band was also detected on PAGE. Furthermore, protease activity was greatly improved by performing autolysis (Table 4). These results indicate that the protease can be efficiently secreted and produced by using a mutant protease precursor having a modified prosequence.
- Example 6 Secretion production of mutant protease precursor 2 Using the various mutant protease precursor gene expression vectors obtained in Examples 2 and 4, the treatments described in Comparative Examples 2 to 6 were performed to evaluate the secretory production of the mutant protease precursor in Pichia yeast. As a result, protease activity was observed in the culture supernatant (Table 5), and a precursor band was also detected on PAGE. Furthermore, protease activity was greatly improved by performing autolysis treatment (Table 5). As a result of the SDS-PAGE analysis of the sample before and after the self-digestion treatment, the protease precursor band disappeared by the treatment and was converted to the protease band (FIG. 2). These results indicate that the protease can be efficiently secreted and produced by using a mutant protease precursor having a modified prosequence.
- Example 7 Construction of mutant protease precursor expression vector 5 Using the expression vector of the N7NK mutation precursor gene constructed in Example 2 as a template, PCR was performed using the combinations of primers (1stPCR-1, 1stPCR-2) shown in Table 6 below. PCR was carried out with primers 7 and 8 using a mixture of fragments as a template to prepare various mutant protease precursor genes with MF sequences.
- mutant protease precursor gene prepared above was treated with BglII and inserted into the BglII site of pUC-PaoxTaoxHIS4 prepared in Comparative Example 1 to construct various mutant protease precursor gene expression vectors with MF sequences. .
- a K residue is inserted between residues corresponding to the wild-type precursor N7 and I8, and each amino acid residue from G1 to I5 is replaced with another amino acid residue.
- Example 8 Secretory production of mutant protease precursor 3 Using the various mutant protease precursor gene expression vectors obtained in Example 7, the treatments described in Comparative Examples 2 to 6 were performed to evaluate the secretory production of the mutant protease precursor in Pichia yeast. As a result, protease activity was observed in the culture supernatant (Table 7), and a precursor band was also detected on PAGE. Furthermore, protease activity was greatly improved by performing autolysis treatment (Table 7).
- Example 9 Construction of mutant protease precursor expression vector 6 Using the expression vector of the N7EK mutation precursor gene constructed in Example 4 as a template, PCR was performed using the combinations of primers (1stPCR-1, 1stPCR-2) shown in Table 8 below. PCR was carried out with primers 7 and 8 using a mixture of fragments as a template to prepare various mutant protease precursor genes with MF sequences.
- the mutant protease precursor gene prepared above was treated with BglII and inserted into the BglII site of pUC-PaoxTaoxHIS4 prepared in Comparative Example 1 to construct various mutant protease precursor gene expression vectors with MF sequences. .
- mutation precursors have mutations in which a K residue is inserted between residues corresponding to wild-type precursors N7 and I8, and a residue corresponding to N7 is substituted with an E residue. Furthermore, it has a mutation in which R111, which is one of the sites capable of causing autolysis within the active form, is substituted with another amino acid residue.
- Example 10 Secretory production of mutant protease precursor 4 Using the various mutant protease precursor gene expression vectors obtained in Example 9, the treatments described in Comparative Examples 2 to 6 were performed to evaluate the secretory production of the mutant protease precursor in Pichia yeast. As a result, protease activity was observed in the culture supernatant (Table 9), and a precursor band was also detected on PAGE. Furthermore, protease activity was greatly improved by performing autolysis treatment (Table 9).
- Example 11 Construction of a mutant protease precursor expression vector under the GAP promoter
- the N7EK-R111A mutant precursor gene expression vector constructed in Example 9 was subjected to BamHI treatment, subjected to agarose gel electrophoresis, and the above vector excluding the AOX1 promoter The region was purified.
- a nucleic acid fragment added with a BamHI recognition sequence on both sides of the GAP promoter (SEQ ID NO: 82) was prepared by PCR using primers 75 (SEQ ID NO: 83) and 76 (SEQ ID NO: 84).
- An expression vector was constructed that was inserted into the BamHI site of the vector region to express the N7EK-R111A mutant precursor gene under the GAP promoter.
- Example 12 Secretory production of mutant protease precursor 4 Using the expression vector that expresses the N7EK-R111A mutant precursor gene under the GAP promoter obtained in Example 11, the treatment described in Comparative Examples 2 to 6 was performed, and the mutant protease precursor in Pichia yeast was treated. Secretory production was evaluated. As a result, protease activity was observed in the culture supernatant (Table 10), and a precursor band was also detected on PAGE. Furthermore, protease activity was greatly improved by carrying out autolysis treatment (Table 10).
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
(1) 酵母内で機能する分泌シグナル配列と、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのプロ配列に変異が導入され、C末端にアルギニン又はリジン残基を有するプロ配列と、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのアミノ酸配列とをN末端側からC末端側にこの順に有する融合タンパク質をコードする遺伝子を酵母で発現させることを含む、酵母におけるプロテアーゼの製造方法。
(2) 酵母の培養上清中に、前記プロテアーゼと、前記プロ配列と前記プロテアーゼのアミノ酸配列とからなるプロテアーゼ前駆体とが1:1以上の活性比で分泌される、(1)に記載の方法。
(3) 培養上清中に発現したプロテアーゼにより、培養上清中に発現したプロテアーゼ前駆体がプロテアーゼに変換される、(1)叉は(2)に記載の方法。
(4) フザリウム・オキシスポラム由来トリプシン様プロテアーゼが、下記(a)~(c)の何れかである、(1)から(3)の何れか一に記載の方法。
(a)配列番号67のアミノ酸配列からなるプロテアーゼ;
(b)配列番号67のアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ;又は
(c)配列番号67のアミノ酸配列において1又は数個のアミノ酸が置換、欠失及び/又は付加されたアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ。
(5) 酵母内で機能する分泌シグナル配列が、酵母MF配列である、(1)から(4)の何れか一に記載の方法。
(6) プロ配列が、Ala- Pro-Gln-Glu-Ile-Pro-Asnで示されるアミノ酸配列に対して1~数個のアミノ酸が付加、欠失又は置換したアミノ酸配列であり、C末端にアルギニン又はリジン残基を有し、酵母においてそのC末端で切断されてプロテアーゼ前駆体からプロテアーゼが生成するアミノ酸配列である、(1)から(5)の何れか一に記載の方法。
(7) プロ配列が、
Ala- Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Xdd-Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Gln-Glu-Ile-Pro-Xaa-Xbb、
Glu-Ile-Pro-Xaa-Xbb、
Ile-Pro-Xaa-Xbb、
Pro-Xaa-Xbb、又は
Xaa-Xbb
(式中、Xaaは任意のアミノ酸残基を示し、XbbはArg又はLys残基を示し、Xccは任意のアミノ酸残基を示し、Xddは任意のアミノ酸残基を示す)
の何れかで示されるアミノ酸配列である、(1)から(6)の何れか一に記載の方法。
(8) フザリウム・オキシスポラム由来トリプシン様プロテアーゼのアミノ酸配列のN末端側に、C末端にアルギニン又はリジン残基を有するプロ配列が融合しているプロテアーゼ前駆体であって、
(i)前記プロテアーゼ前駆体を酵母の培養上清中に発現させた場合、前記プロテアーゼと、前記プロ配列と前記プロテアーゼのアミノ酸配列とからなるプロテアーゼ前駆体とが1:1以上の活性比で分泌され、かつ
(ii)前記発現したプロテアーゼにより、前記発現したプロテアーゼ前駆体をプロテアーゼに変換することが可能である、
プロテアーゼ前駆体。
(9) フザリウム・オキシスポラム由来トリプシン様プロテアーゼが、下記(a)~(c)の何れかである、(8)に記載のプロテアーゼ前駆体:
(a)配列番号67のアミノ酸配列からなるプロテアーゼ;
(b)配列番号67のアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ;又は
(c)配列番号67のアミノ酸配列において1又は数個のアミノ酸が置換、欠失及び/又は付加されたアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ。
(10) プロ配列が、Ala- Pro-Gln-Glu-Ile-Pro-Asnで示されるアミノ酸配列に対して1~数個のアミノ酸が付加、欠失又は置換したアミノ酸配列であり、C末端にアルギニン又はリジン残基を有し、酵母においてそのC末端で切断されてプロテアーゼ前駆体からプロテアーゼが生成するアミノ酸配列である、(8)又は(9)に記載のプロテアーゼ前駆体。
(11) プロ配列が、
Ala- Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Xdd-Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Gln-Glu-Ile-Pro-Xaa-Xbb、
Glu-Ile-Pro-Xaa-Xbb、
Ile-Pro-Xaa-Xbb、
Pro-Xaa-Xbb、又は
Xaa-Xbb
(式中、Xaaは任意のアミノ酸残基を示し、XbbはArg又はLys残基を示し、Xccは任意のアミノ酸残基を示し、Xddは任意のアミノ酸残基を示す)
の何れかで示されるアミノ酸配列である、(8)から(10)の何れか一に記載のプロテアーゼ前駆体。
(12) 酵母内で機能する分泌シグナル配列と、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのプロ配列に変異が導入され、C末端にアルギニン又はリジン残基を有するプロ配列と、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのアミノ酸配列とをN末端側からC末端側にこの順に有する融合タンパク質をコードするDNAを有する組み換え発現ベクター。
(13) フザリウム・オキシスポラム由来トリプシン様プロテアーゼが、下記(a)~(c)の何れかである、(12)に記載の組み換え発現ベクター:
(a)配列番号67のアミノ酸配列からなるプロテアーゼ;
(b)配列番号67のアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ;又は
(c)配列番号67のアミノ酸配列において1又は数個のアミノ酸が置換、欠失及び/又は付加されたアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ。
(14) 酵母内で機能する分泌シグナル配列が、酵母MF配列である、(12)又は(13)に記載の組み換え発現ベクター。
(15) プロ配列が、Ala- Pro-Gln-Glu-Ile-Pro-Asnで示されるアミノ酸配列に対して1~数個のアミノ酸が付加、欠失又は置換したアミノ酸配列であって、酵母においてそのC末端で切断されてプロテアーゼ前駆体からプロテアーゼが生成するアミノ酸配列である、(12)から(14)の何れか一に記載の組み換え発現ベクター。
(16) プロ配列が、
Ala- Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Xdd-Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Gln-Glu-Ile-Pro-Xaa-Xbb、
Glu-Ile-Pro-Xaa-Xbb、
Ile-Pro-Xaa-Xbb、
Pro-Xaa-Xbb、又は
Xaa-Xbb
(式中、Xaaは任意のアミノ酸残基を示し、XbbはArg又はLys残基を示し、Xccは任意のアミノ酸残基を示し、Xddは任意のアミノ酸残基を示す)
の何れかで示されるアミノ酸配列である、(12)から(15)の何れか一に記載の組み換え発現ベクター。
(17) (12)から(16)の何れか一に記載の組み換え発現ベクターを有する形質転換酵母。
さらに本発明によれば、以下の発明が提供される。
(A) 酵母で発現したフザリウム・オキシスポラム由来トリプシン様プロテアーゼを含む、酵母培養物由来プロテアーゼ組成物。
(B) フザリウム・オキシスポラム由来トリプシン様プロテアーゼが、下記(a)~(c)の何れかである、(A)に記載の酵母培養物由来プロテアーゼ組成物;
(a)配列番号67のアミノ酸配列からなるプロテアーゼ;
(b)配列番号67のアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ;又は
(c)配列番号67のアミノ酸配列において1又は数個のアミノ酸が置換、欠失及び/又は付加されたアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ。
[酵母におけるプロテアーゼの製造]
本発明においては、酵母内で機能する分泌シグナル配列と、プロ配列(より詳細には、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのプロ配列に変異を導入し、C末端にアルギニン又はリジン残基を有するプロ配列)と、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのアミノ酸配列とを、N末端側からC末端側にこの順に有する融合タンパク質をコードする遺伝子を酵母で発現させることによって、酵母においてプロテアーゼを製造する。
ここでいう活性比とは、培養上清中のプロテアーゼ活性量(培養後に自己消化によるプロテアーゼ前駆体からプロテアーゼへの変換を行う前の培養上清中のプロテアーゼ活性量)をプロテアーゼの発現量とし、自己消化後のプロテアーゼ活性量から培養上清中のプロテアーゼ活性量を引いた活性量をプロテアーゼ前駆体の発現量とした場合の発現量比のことを示す。
本発明で言うフザリウム・オキシスポラム由来トリプシン様プロテアーゼとは、フザリウム・オキシスポラムが発現するトリプシン様プロテアーゼ又はその改変体を意味する。ザリウム・オキシスポラムが発現するトリプシン様プロテアーゼは、配列番号67のアミノ酸配列からなるプロテアーゼである。
(b)配列番号67のアミノ酸配列と90%以上(好ましくは95%以上、より好ましくは98%以上)の配列同一性を有するアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ;又は
(c)配列番号67のアミノ酸配列において1又は数個(好ましくは1~10個、より好ましくは1~5個、さらに好ましくは1~3個)のアミノ酸が置換、欠失及び/又は付加されたアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ。
を発現させてもよい。例としては、実施例9および10に記載した配列番号67のR104残基(104番目のアミノ酸残基であるArg残基)を他のアミノ酸に置換した変異体が挙げられる。
(第1群:中性非極性アミノ酸)Gly,Ala,Val,Leu,Ile,Met,Cys,Pro,Phe;
(第2群:中性極性アミノ酸)Ser,Thr,Gln,Asn,Trp,Tyr;
(第3群:酸性アミノ酸)Glu,Asp;
(第4群:塩基性アミノ酸)His,Lys,Arg:
本発明で使用する酵母内で機能する分泌シグナル配列は、細胞質内で生合成されたタンパク質の小胞体への輸送及び局在化を指示する配列であり、タンパク質のN末端に存在することにより、発現したタンパク質を宿主細胞である酵母外に分泌させる機能を有するペプチドである。分泌シグナル配列は、通常、分泌性タンパク質が細胞内から細胞膜を通過して細胞外へ分泌される際にシグナルペプチダーゼにより分解されることにより除去される。
本発明で使用するプロ配列は、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのプロ配列に変異を導入することにより得られるものであり、かつそのC末端にアルギニン又はリジン残基を有していることが好ましい。
本発明で使用するプロ配列は、酵母においてそのC末端で切断されてプロテアーゼ前駆体からプロテアーゼが生成するアミノ酸配列である。アミノ酸の置換の場合には、置換するアミノ酸は、置換前のアミノ酸と類似の性質を有するアミノ酸(同族アミノ酸)であることが好ましい。同族アミノ酸については、本明細書中上記した通りである。
Ala- Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Xdd-Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Gln-Glu-Ile-Pro-Xaa-Xbb、
Glu-Ile-Pro-Xaa-Xbb、
Ile-Pro-Xaa-Xbb、
Pro-Xaa-Xbb、又は
Xaa-Xbb
(式中、Xaaは任意のアミノ酸残基を示し、XbbはArg又はLys残基を示し、Xccは任意のアミノ酸残基を示し、Xddは任意のアミノ酸残基を示す)
の何れかで示されるアミノ酸配列を挙げることができる。
Xcc及びXddは、好ましくは中性アミノ酸残基(Gly、Ala、Val、Leu、Ile、Cys、Met、Ser、Thr、Tyr、Phe、Trp、Pro、Asn、Gln)であり、より好ましくは脂肪族アミノ酸残基(Gly、Ala、Val、Leu、Ile)であり、さらに好ましくはAlaである。
本発明では、酵母内で機能する分泌シグナル配列と、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのプロ配列に変異が導入され、C末端にアルギニン又はリジン残基を有するプロ配列と、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのアミノ酸配列とをN末端側からC末端側にこの順に有する融合タンパク質をコードするDNAを有する組み換え発現ベクターを用いて、酵母においてフザリウム・オキシスポラム由来トリプシン様プロテアーゼを発現及び分泌させる。
本発明によれば、上記した本発明の組み換え発現ベクターを有する形質転換酵母が提供される。
酵母の種類は、特に限定されないが、メタノール資化性酵母がより好ましく、オガタエア属(Ogataea)やコマガタエラ属(Komagataella)に属するメタノール資化性酵母がさらに好ましい。オガタエア属に属するメタノール資化性酵母の中でも、オガタエア・ポリモルファ(Ogataea polymorpha)、オガタエア・ミニュータ(Ogataea minuta)が好ましく、コマガタエラ属に属するメタノール資化性酵母では、コマガタエア・パストリス(Komagataella pastoris)が好ましい。
本発明によれば、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのアミノ酸配列のN末端側に、C末端にアルギニン又はリジン残基を有するプロ配列が融合しているプロテアーゼ前駆体が提供される。
(i)前記プロテアーゼ前駆体を酵母の培養上清中に発現させた場合、前記プロテアーゼと、前記プロテアーゼ前駆体とが1:1以上の比率で分泌し、かつ
(ii)前記発現したプロテアーゼにより、前記発現したプロテアーゼ前駆体をプロテアーゼに変換することが可能である、
という特徴を有している。
本発明における分泌生産とは、形質転換酵母を液体培養して、菌体内部でなく培養上清にプロテアーゼ前駆体及びプロテアーゼを蓄積させることを指す。
本発明によれば、酵母で発現したフザリウム・オキシスポラム由来トリプシン様プロテアーゼを含む、酵母培養物由来プロテアーゼ組成物が提供される。本発明の組成物は、酵母培養物由来プロテアーゼ組成物であり、酵母培養物由来成分を含む場合がある。また、本発明におけるフザリウム・オキシスポラム由来トリプシン様プロテアーゼは、酵母で発現したものであり、酵母における翻訳語修飾を受けているものである場合がある。
(a)配列番号67のアミノ酸配列からなるプロテアーゼ;
(b)配列番号67のアミノ酸配列と90%以上(好ましくは95%以上、より好ましくは98%以上)の配列同一性を有するアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ;又は
(c)配列番号67のアミノ酸配列において1又は数個(好ましくは1~10個、より好ましくは1~5個、さらに好ましくは1~3個)のアミノ酸が置換、欠失及び/又は付加されたアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ。
上記の通り回収したフザリウム・オキシスポラム由来トリプシン様プロテアーゼは、そのまま使用することもできるが、各種の製剤化処理を施してから使用してもよい。
PCRにはPrime STAR HS DNA Polymerase(タカラバイオ社製)等を用い、反応条件は添付のマニュアルに記載の方法で行った。染色体DNAの調製は、コマガタエラ・パストリスATCC76273株からGenとるくんTM(タカラバイオ社製)等を用いて、これに記載の条件で実施した。
HindIII-BamHI-BglII-XbaI-EcoRIのマルチクローニングサイトをもつ遺伝子断片(配列番号6)を全合成し、これをpUC19(タカラバイオ社製、Code No. 3219)のHindIII-EcoRIサイト間に挿入して、pUC-1を構築した。
また、AOX1プロモーターの両側にBamHI認識配列を付加した核酸断片を、プライマー1(配列番号7)及び2(配列番号8)を用いたPCRにより調製し、BamHI処理後にpUC-1のBamHIサイトに挿入して、pUC-Paoxを構築した。
次に、HIS4遺伝子の両側にEcoRI認識配列を付加した核酸断片を、プライマー5(配列番号11)及び6(配列番号12)を用いたPCRにより調製し、EcoRI処理後にpUC-PaoxTaoxのEcoRIサイトに挿入して、pUC-PaoxTaoxHIS4を構築した。
比較例1で構築した野生型プロテアーゼ前駆体発現ベクターを用いて、以下のようにコマガタエラ・パストリスを形質転換した。
コマガタエラ・パストリスATCC76273株由来ヒスチジン要求性株を3mlのYPD培地(1% yeast extract bacto(Difco社製)、2% polypeptone(日本製薬社製)、2% glucose)に接種し、30℃で一晩振盪培養して、前培養液を得た。得られた前培養液500μlを50mlのYPD培地に接種し、OD600が1~1.5になるまで振盪培養後、集菌(3000×g、10分、20℃)し、250μlの1M DTT(終濃度25mM)を含む10mlの50mMリン酸カリウムバッファー,pH7.5に再懸濁した。
比較例1で構築した野生型プロテアーゼ前駆体発現ベクターpUC-PaoxTPTaoxHIS4を用いて大腸菌を形質転換し、得られた形質転換体を2mlのアンピシリン含有2YT培地(1.6% tryptone bacto(Difco社製)、1% yeast extract bacto(Difco社製)、0.5% 塩化ナトリウム、0.01%アンピシリンナトリウム(和光純薬工業社製))で培養し、得られた菌体からQIAprep spin miniprep kit(QIAGEN社製)を用いて、pUC-PaoxTPTaoxHIS4を取得した。本プラスミドをSalI処理し、HIS4遺伝子内のSalI認識配列で切断された直鎖状ベクターを調製した。
比較例2で得られた野生型プロテアーゼ前駆体発現酵母を2mlのBMGY培地(1% yeast extract bacto(Difco社製)、2% polypeptone(日本製薬社製)、0.34% yeast nitrogen base Without Amino Acid and Ammonium Sulfate(Difco社製)、1% Ammonium Sulfate、0.4mg/l Biotin、100mM リン酸カリウム(pH6.0)、1% glycerol、1% Methanol)に接種し、これを30℃、48時間振盪培養後、遠心分離(12000rpm、5分、4℃)により培養上清を回収した。
比較例3で得られた培養上清のSDS-PAGE解析を実施した。
12μlの培養上清と3μlの5×サンプルバッファー(0.25M Tris-HCl(pH6.8)、50% Glycerol、6.7% SDS、0.01% BPB)を混合し、95℃-8min処理をした。本サンプルを分子量マーカー(Precision Plus Protein’TM Dual Color Standards、バイオラッド社製)と共に、 e-PAGELゲル(E-R15L、ATTO社製)を用いてSDS-PAGE電気泳動に供した。泳動後、ゲルを15分間水洗し、染色液(Bio-Safe CBB G-250ステイン;Bio-Rad社製)により30分染色したのち、水で脱色した。その結果、プロテアーゼ前駆体のアミノ酸配列から推定される分子量に相当する領域にバンドは認められた(図1、lane1)。
培養上清中に存在するプロテアーゼ前駆体を自己消化により活性体への変換は以下のように実施した。
培養上清 500μlを、Amicon Ultracel-3K(メルクミリポア製)を用いて、活性測定用buffer(10mM TrisHCl (pH8.0), 10mM MgCl2)に置換した。その後、同bufferを用いて、液量を500μlに調整して、15℃で24~48時間インキュベートした。
各サンプル中に含まれるプロテアーゼ活性は以下の方法で測定した。
活性測定用buffer 990μlに、2.5mM N-Benzoyl-DL-arginine-p-nitroanilideHCl (nacalai社製) のDMSO溶液 10μlを加えた後に、サンプル 1~10μlを添加後、初発の410nmの吸光度を測定する。そして37℃で1時間インキュベートし、反応後の410nmの吸光度を測定した。反応前後の410nmの吸光度変化から、遊離したp-nitroaniline量を算出して、プロテアーゼ活性を計算した。なお、1min間に1μmolのp-nitroanilineを生成する酵素量を1ユニットと定義した。
上記方法で比較例3で得られた培養上清および比較例5で得られた自己消化後の溶液中のプロテアーゼ活性を測定したが、活性は検出できなかった(表1)。
MF配列が付与された野生型プロテアーゼ前駆体遺伝子の合成遺伝子をテンプレートにプロテアーゼ遺伝子をPCRで調製した。プライマー7及びプライマー9(配列番号15)、プライマー10(配列番号16)及びプライマー8を用いたPCRを実施し、それぞれのPCRの増幅断片を混合した後に、プライマー7及びプライマー8でPCRを実施し、MF配列が付与されたプロテアーゼ遺伝子を調製した。
上記で調製したプロテアーゼ遺伝子をBglII処理し、比較例1で調製したpUC-PaoxTaoxHIS4のBglIIサイトに挿入して、MF配列が付与されたプロテアーゼ遺伝子発現ベクターを構築した。
比較例7で構築したベクターを用いて、比較例2~6の処理を行い、ピキア酵母でのプロテアーゼの分泌生産を評価した。その結果、培養上清中に少量のプロテアーゼ活性を認めたものの、PAGE上でのプロテアーゼのバンドは認められなかった(図1 lane 2, 表1)。本結果は、プロテーゼをピキア酵母で高分泌させるのは困難であることを示している。
MF配列が付与された野生型プロテアーゼ前駆体遺伝子の合成遺伝子をテンプレートにブタトリプシン由来プロ配列をもつ変異プロテアーゼ前駆体遺伝子をPCRで調製した。プライマー7及びプライマー11(配列番号17)、プライマー12(配列番号18)及びプライマー8を用いたPCRを実施し、それぞれのPCRの増幅断片を混合した後に、プライマー7及びプライマー8でPCRを実施し、MF配列が付与された変異プロテアーゼ前駆体遺伝子を調製した。
上記で調製したプロテアーゼ遺伝子をBglII処理し、比較例1で調製したpUC-PaoxTaoxHIS4のBglIIサイトに挿入して、MF配列が付与された変異プロテアーゼ前駆体遺伝子発現ベクターを構築した。
比較例9で構築したベクターを用いて、比較例2~6の処理を行い、ピキア酵母での変異プロテアーゼ前駆体の分泌生産を評価した。その結果、培養上清中にプロテアーゼ活性は認められず(表1)、PAGE上ではアミノ酸配列から推測されるサイズとは異なるバンドが認められた。本結果は、自己消化による前駆体から活性型への変換例が報告されているブタ由来トリプシンのプロ配列を用いても、本プロテアーゼではうまく機能しないことを示している。
MF配列が付与された野生型プロテアーゼ前駆体遺伝子の合成遺伝子をテンプレートにN7NR変異前駆体遺伝子をPCRで調製した。プライマー7及びプライマー13(配列番号19)、プライマー14(配列番号20)及びプライマー8を用いたPCRを実施し、それぞれのPCRの増幅断片を混合した後に、プライマー7及びプライマー8でPCRを実施し、MF配列が付与されたN7NR変異前駆体遺伝子を調製した。
上記で調製した変異型プロテアーゼ前駆体遺伝子をBglII処理し、比較例1で調製したpUC-PaoxTaoxHIS4のBglIIサイトに挿入して、MF配列が付与された各種変異プロテアーゼ前駆体遺伝子発現ベクターを構築した。
この変異前駆体は、野生型前駆体のN7とI8に相当する残基間にR残基が挿入された変異を有する。
MF配列が付与された野生型プロテアーゼ前駆体遺伝子の合成遺伝子をテンプレートにN7NK変異前駆体遺伝子をPCRで調製した。プライマー7及びプライマー15(配列番号21)、プライマー16(配列番号22)及びプライマー8を用いたPCRを実施し、それぞれのPCRの増幅断片を混合した後に、プライマー7及びプライマー8でPCRを実施し、MF配列が付与されたN24NK変異前駆体遺伝子を調製した。
上記で調製した変異型プロテアーゼ前駆体遺伝子をBglII処理し、比較例1で調製したpUC-PaoxTaoxHIS4のBglIIサイトに挿入して、MF配列が付与された各種変異型プロテアーゼ前駆体遺伝子発現ベクターを構築した。
この変異前駆体は、野生型前駆体のN7とI8に相当する残基間にK残基が挿入された変異を有する。
実施例1で構築したN7NR変異前駆体遺伝子の発現ベクターをテンプレートに、以下の表2に示した、各プライマーの組合せ(1stPCR-1、1stPCR-2)を用いてPCRを行い、得られた各断片を混合したものをテンプレートに、プライマー7およびプライマー8でPCRを行い、MF配列が付与された各種変異型プロテアーゼ前駆体遺伝子を調製した。
上記で調製した変異型プロテアーゼ前駆体遺伝子をBglII処理し、比較例1で調製したpUC-PaoxTaoxHIS4のBglIIサイトに挿入して、MF配列が付与された各種変異型プロテアーゼ前駆体遺伝子発現ベクターを構築した。
これらの変異前駆体は、野生型前駆体のN7とI8に相当する残基間にR残基が挿入され、かつN7に相当する残基が別のアミノ酸残基に置換された変異を有する。
実施例2で構築したN7NK変異前駆体遺伝子の発現ベクターをテンプレートに、以下の表3に示した、各プライマーの組合せ(1stPCR-1、1stPCR-2)を用いてPCRを行い、得られた各断片を混合したものをテンプレートに、プライマー7およびプライマー8でPCRを行い、MF配列が付与された各種変異型プロテアーゼ前駆体遺伝子を調製した。
上記で調製した変異型プロテアーゼ前駆体遺伝子をBglII処理し、比較例1で調製したpUC-PaoxTaoxHIS4のBglIIサイトに挿入して、MF配列が付与された各種変異型プロテアーゼ前駆体遺伝子発現ベクターを構築した。
これらの変異前駆体の一部は、野生型前駆体のN7とI8に相当する残基間にK残基が挿入され、かつN7に相当する残基が別のアミノ酸残基に置換された変異を有する。また、別のこれらの変異前駆体の一部は、野生型前駆体のN7とI8に相当する残基間にK残基が挿入され、プロ配列の長さが異なる変異を有する
実施例1および3で得られた各種変異型プロテアーゼ前駆体遺伝子発現ベクターを用いて、比較例2~6に記載の処理を行い、ピキア酵母での変異型プロテアーゼ前駆体の分泌生産を評価した。その結果、培養上清中にプロテアーゼ活性が認められ(表4)、PAGE上において前駆体バンドも検出された。さらに、自己消化処理を行うことにより、プロテアーゼ活性が大きく向上した(表4)。
これらの結果は、改変したプロ配列を有する変異型プロテアーゼ前駆体を用いることにより、効率的にプロテアーゼを分泌生産できることを示している。
実施例2および4で得られた各種変異型プロテアーゼ前駆体遺伝子発現ベクターを用いて、比較例2~6に記載の処理を行い、ピキア酵母での変異型プロテアーゼ前駆体の分泌生産を評価した。その結果、培養上清中にプロテアーゼ活性が認められ(表5)、PAGE上において前駆体バンドも検出された。さらに、自己消化処理を行うことにより、プロテアーゼ活性が大きく向上した(表5)。自己消化処理の前後のサンプルのSDS-PAGE解析の結果、処理によりプロテアーゼ前駆体のバンドが消失し、プロテアーゼのバンドに変換されていた(図2)。
これらの結果は、改変したプロ配列を有する変異型プロテアーゼ前駆体を用いることにより、効率的にプロテアーゼを分泌生産できることを示している。
実施例2で構築したN7NK変異前駆体遺伝子の発現ベクターをテンプレートに、以下の表6に示した、各プライマーの組合せ(1stPCR-1、1stPCR-2)を用いてPCRを行い、得られた各断片を混合したものをテンプレートに、プライマー7およびプライマー8でPCRを行い、MF配列が付与された各種変異型プロテアーゼ前駆体遺伝子を調製した。
実施例7で得られた各種変異型プロテアーゼ前駆体遺伝子発現ベクターを用いて、比較例2~6に記載の処理を行い、ピキア酵母での変異型プロテアーゼ前駆体の分泌生産を評価した。その結果、培養上清中にプロテアーゼ活性が認められ(表7)、PAGE上において前駆体バンドも検出された。さらに、自己消化処理を行うことにより、プロテアーゼ活性が大きく向上した(表7)。
実施例4で構築したN7EK変異前駆体遺伝子の発現ベクターをテンプレートに、以下の表8に示した、各プライマーの組合せ(1stPCR-1、1stPCR-2)を用いてPCRを行い、得られた各断片を混合したものをテンプレートに、プライマー7およびプライマー8でPCRを行い、MF配列が付与された各種変異型プロテアーゼ前駆体遺伝子を調製した。
上記で調製した変異型プロテアーゼ前駆体遺伝子をBglII処理し、比較例1で調製したpUC-PaoxTaoxHIS4のBglIIサイトに挿入して、MF配列が付与された各種変異型プロテアーゼ前駆体遺伝子発現ベクターを構築した。
実施例9で得られた各種変異型プロテアーゼ前駆体遺伝子発現ベクターを用いて、比較例2~6に記載の処理を行い、ピキア酵母での変異型プロテアーゼ前駆体の分泌生産を評価した。その結果、培養上清中にプロテアーゼ活性が認められ(表9)、PAGE上において前駆体バンドも検出された。さらに、自己消化処理を行うことにより、プロテアーゼ活性が大きく向上した(表9)。
実施例11: GAPプロモーター下での変異プロテアーゼ前駆体発現ベクターの構築
実施例9で構築したN7EK-R111A変異前駆体遺伝子の発現ベクターをBamHI処理後に、アガロースゲル電気泳動し、AOX1プロモーターを除く上記ベクター領域を精製した。次に、GAPプロモーター(配列番号82)の両側にBamHI認識配列を付加した核酸断片を、プライマー75(配列番号83)及び76(配列番号84)を用いたPCRにより調製し、BamHI処理後に上記のベクター領域のBamHIサイトに挿入して、GAPプロモーター下でのN7EK-R111A変異前駆体遺伝子が発現する発現ベクターを構築した。
実施例11で得られたGAPプロモーター下でのN7EK-R111A変異前駆体遺伝子が発現する発現ベクターを用いて、比較例2~6に記載の処理を行い、ピキア酵母での変異型プロテアーゼ前駆体の分泌生産を評価した。その結果、培養上清中にプロテアーゼ活性が認められ(表10)、PAGE上において前駆体バンドも検出された。さらに、自己消化処理を行うことにより、プロテアーゼ活性が大きく向上した(表10)。
Claims (17)
- 酵母内で機能する分泌シグナル配列と、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのプロ配列に変異が導入され、C末端にアルギニン又はリジン残基を有するプロ配列と、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのアミノ酸配列とをN末端側からC末端側にこの順に有する融合タンパク質をコードする遺伝子を酵母で発現させることを含む、酵母におけるプロテアーゼの製造方法。
- 酵母の培養上清中に、前記プロテアーゼと、前記プロ配列と前記プロテアーゼのアミノ酸配列とからなるプロテアーゼ前駆体とが1:1以上の活性比で分泌される、請求項1に記載の方法。
- 培養上清中に発現したプロテアーゼにより、培養上清中に発現したプロテアーゼ前駆体がプロテアーゼに変換される、請求項1叉は2に記載の方法。
- フザリウム・オキシスポラム由来トリプシン様プロテアーゼが、下記(a)~(c)の何れかである、請求項1から3の何れか一項に記載の方法。
(a)配列番号67のアミノ酸配列からなるプロテアーゼ;
(b)配列番号67のアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ;又は
(c)配列番号67のアミノ酸配列において1又は数個のアミノ酸が置換、欠失及び/又は付加されたアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ。 - 酵母内で機能する分泌シグナル配列が、酵母MF配列である、請求項1から4の何れか一項に記載の方法。
- プロ配列が、Ala- Pro-Gln-Glu-Ile-Pro-Asnで示されるアミノ酸配列に対して1~数個のアミノ酸が付加、欠失又は置換したアミノ酸配列であり、C末端にアルギニン又はリジン残基を有し、酵母においてそのC末端で切断されてプロテアーゼ前駆体からプロテアーゼが生成するアミノ酸配列である、請求項1から5の何れか一項に記載の方法。
- プロ配列が、
Ala- Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Xdd-Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Gln-Glu-Ile-Pro-Xaa-Xbb、
Glu-Ile-Pro-Xaa-Xbb、
Ile-Pro-Xaa-Xbb、
Pro-Xaa-Xbb、又は
Xaa-Xbb
(式中、Xaaは任意のアミノ酸残基を示し、XbbはArg又はLys残基を示し、Xccは任意のアミノ酸残基を示し、Xddは任意のアミノ酸残基を示す)
の何れかで示されるアミノ酸配列である、請求項1から6の何れか一項に記載の方法。 - フザリウム・オキシスポラム由来トリプシン様プロテアーゼのアミノ酸配列のN末端側に、C末端にアルギニン又はリジン残基を有するプロ配列が融合しているプロテアーゼ前駆体であって、
(i)前記プロテアーゼ前駆体を酵母の培養上清中に発現させた場合、前記プロテアーゼと、前記プロ配列と前記プロテアーゼのアミノ酸配列とからなるプロテアーゼ前駆体とが1:1以上の活性比で分泌され、かつ
(ii)前記発現したプロテアーゼにより、前記発現したプロテアーゼ前駆体をプロテアーゼに変換することが可能である、
プロテアーゼ前駆体。 - フザリウム・オキシスポラム由来トリプシン様プロテアーゼが、下記(a)~(c)の何れかである、請求項8に記載のプロテアーゼ前駆体:
(a)配列番号67のアミノ酸配列からなるプロテアーゼ;
(b)配列番号67のアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ;又は
(c)配列番号67のアミノ酸配列において1又は数個のアミノ酸が置換、欠失及び/又は付加されたアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ。 - プロ配列が、Ala- Pro-Gln-Glu-Ile-Pro-Asnで示されるアミノ酸配列に対して1~数個のアミノ酸が付加、欠失又は置換したアミノ酸配列であり、C末端にアルギニン又はリジン残基を有し、酵母においてそのC末端で切断されてプロテアーゼ前駆体からプロテアーゼが生成するアミノ酸配列である、請求項8又は9に記載のプロテアーゼ前駆体。
- プロ配列が、
Ala- Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Xdd-Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Gln-Glu-Ile-Pro-Xaa-Xbb、
Glu-Ile-Pro-Xaa-Xbb、
Ile-Pro-Xaa-Xbb、
Pro-Xaa-Xbb、又は
Xaa-Xbb
(式中、Xaaは任意のアミノ酸残基を示し、XbbはArg又はLys残基を示し、Xccは任意のアミノ酸残基を示し、Xddは任意のアミノ酸残基を示す)
の何れかで示されるアミノ酸配列である、請求項8から10の何れか一項に記載のプロテアーゼ前駆体。 - 酵母内で機能する分泌シグナル配列と、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのプロ配列に変異が導入され、C末端にアルギニン又はリジン残基を有するプロ配列と、フザリウム・オキシスポラム由来トリプシン様プロテアーゼのアミノ酸配列とをN末端側からC末端側にこの順に有する融合タンパク質をコードするDNAを有する組み換え発現ベクター。
- フザリウム・オキシスポラム由来トリプシン様プロテアーゼが、下記(a)~(c)の何れかである、請求項12に記載の組み換え発現ベクター:
(a)配列番号67のアミノ酸配列からなるプロテアーゼ;
(b)配列番号67のアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ;又は
(c)配列番号67のアミノ酸配列において1又は数個のアミノ酸が置換、欠失及び/又は付加されたアミノ酸配列からなり、配列番号67のアミノ酸配列からなるプロテアーゼと同等のトリプシン様プロテアーゼ活性を有するプロテアーゼ。 - 酵母内で機能する分泌シグナル配列が、酵母MF配列である、請求項12又は13に記載の組み換え発現ベクター。
- プロ配列が、Ala- Pro-Gln-Glu-Ile-Pro-Asnで示されるアミノ酸配列に対して1~数個のアミノ酸が付加、欠失又は置換したアミノ酸配列であって、酵母においてそのC末端で切断されてプロテアーゼ前駆体からプロテアーゼが生成するアミノ酸配列である、請求項12から14の何れか一項に記載の組み換え発現ベクター。
- プロ配列が、
Ala- Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Xdd-Xcc-Ala- Pro-Gln-Glu-Ile-Pro-Xaa- Xbb、
Pro-Gln-Glu-Ile-Pro-Xaa-Xbb、
Gln-Glu-Ile-Pro-Xaa-Xbb、
Glu-Ile-Pro-Xaa-Xbb、
Ile-Pro-Xaa-Xbb、
Pro-Xaa-Xbb、又は
Xaa-Xbb
(式中、Xaaは任意のアミノ酸残基を示し、XbbはArg又はLys残基を示し、Xccは任意のアミノ酸残基を示し、Xddは任意のアミノ酸残基を示す)
の何れかで示されるアミノ酸配列である、請求項12から15の何れか一項に記載の組み換え発現ベクター。 - 請求項12から16の何れか一項に記載の組み換え発現ベクターを有する形質転換酵母。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019507013A JPWO2018174231A1 (ja) | 2017-03-24 | 2018-03-23 | 酵母におけるプロテアーゼの製造方法 |
EP18770777.3A EP3604508A4 (en) | 2017-03-24 | 2018-03-23 | METHOD OF PRODUCTION OF PROTEASE IN YEAST |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-058983 | 2017-03-24 | ||
JP2017058983 | 2017-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018174231A1 true WO2018174231A1 (ja) | 2018-09-27 |
Family
ID=63586129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/011631 WO2018174231A1 (ja) | 2017-03-24 | 2018-03-23 | 酵母におけるプロテアーゼの製造方法 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3604508A4 (ja) |
JP (1) | JPWO2018174231A1 (ja) |
WO (1) | WO2018174231A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110467649A (zh) * | 2019-09-12 | 2019-11-19 | 浙江省农业科学院 | 一种抑制血管紧张素转换酶活性的多肽qeip及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994025583A1 (en) | 1993-05-05 | 1994-11-10 | Novo Nordisk A/S | A recombinant trypsin-like protease |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1012307T3 (da) * | 1997-08-22 | 2005-09-05 | Roche Diagnostics Gmbh | Autokatalytisk aktiverbare zymogene proteaseforstadier og deres anvendelse |
-
2018
- 2018-03-23 JP JP2019507013A patent/JPWO2018174231A1/ja active Pending
- 2018-03-23 EP EP18770777.3A patent/EP3604508A4/en not_active Withdrawn
- 2018-03-23 WO PCT/JP2018/011631 patent/WO2018174231A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994025583A1 (en) | 1993-05-05 | 1994-11-10 | Novo Nordisk A/S | A recombinant trypsin-like protease |
Non-Patent Citations (8)
Title |
---|
LING, ZHENMIN ET AL.: "Functional expression of trypsin from Streptomyces griseus by Pichia pastoris", J. IND. MICROBIOL. BIOTECHNOL., vol. 39, 2012, pages 1651 - 1662, XP055545990 * |
METHODS ENZYMOL., vol. 183, 1990, pages 63 |
MIN SHU ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 114, 2015, pages 149 - 155 |
NATALIE E. FARNWORTH ET AL., ENZYME AND MICROBIAL TECHNOLOGY, vol. 33, 2003, pages 85 - 91 |
PRO. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 |
See also references of EP3604508A4 * |
ZHANG, YUNFENG ET AL.: "Improved production of active Streptomyces griseus trypsin with a novel auto-catalyzed strategy", SCIENTIFIC REPORTS, vol. 6, 2016, pages 1 - 11, XP055545983 * |
ZHENMIN LING ET AL., J IND MICROBIOL BIOTECHNOL, vol. 39, 2012, pages 1651 - 1662 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110467649A (zh) * | 2019-09-12 | 2019-11-19 | 浙江省农业科学院 | 一种抑制血管紧张素转换酶活性的多肽qeip及其应用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2018174231A1 (ja) | 2020-01-23 |
EP3604508A4 (en) | 2021-01-20 |
EP3604508A1 (en) | 2020-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1904656B1 (en) | Library of translational fusion partners for producing recombinant proteins and translational fusion partners screened therefrom | |
JP2009507500A (ja) | トリプシンの変異体によるインスリン前駆体の切断 | |
SE513358C2 (sv) | Ciliär neurotropisk ischiasnervprotein faktor, dess framställning och använding i farmaceutisk komposition | |
WO2017101801A1 (zh) | 高效的不依赖锌离子的磷脂酶c突变体 | |
CN108350042A (zh) | 皮肤细胞增殖及抗氧化效果得到增加的肉毒杆菌毒素-人表皮细胞生长因子融合蛋白及含有其作为有效成分的用于皮肤再生及改善皱纹的化妆料组合物 | |
WO1991018101A1 (fr) | Procede de production d'une proteine | |
US9102755B2 (en) | Highly stabilized epidermal growth factor mutants | |
KR20190083307A (ko) | 목적 단백질의 수용성 및 발현량 증가를 위한 융합 태그 및 이의 용도 | |
KR101613302B1 (ko) | Sv82 폴리펩타이드 및 이를 유효성분으로 함유하는 피부 주름 개선 및 탄력 유지용 화장료 조성물 | |
WO2018174231A1 (ja) | 酵母におけるプロテアーゼの製造方法 | |
EP0251730A2 (en) | Production of human lysozyme | |
CN109136209B (zh) | 肠激酶轻链突变体及其应用 | |
Gallagher et al. | Gene-dose-dependent expression of soluble mammalian cytochrome b 5 in Escherichia coli | |
KR20200015012A (ko) | 내열성 탄산무수화효소 변이체 및 이를 포함하는 이산화탄소 포집용 조성물 | |
MXPA04004934A (es) | Metodo mejorado para la produccion recombinante de proteinas. | |
EP0974665A1 (en) | Recombinant yeast pdi and process for preparing the same | |
CN113005111B (zh) | 新型的甘油单-二酰酯脂肪酶 | |
KR101634078B1 (ko) | 봉입체 형성 단백질의 제조방법 | |
JPWO2018021324A1 (ja) | 安定性に優れたリパーゼ活性を有するポリペプチド | |
KR101657298B1 (ko) | 세포 증식 효과가 증가한 인간 상피세포재생인자 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 및 탄력 개선용 화장료 조성물 | |
CN113025595A (zh) | 耐酸脂肪酶 | |
JPH07274970A (ja) | 組換えベクターと、この組換えベクターを保持する形 質転換体、およびこの形質転換体による抗菌性ペプチ ドの製造方法 | |
CN113025596A (zh) | 耐甲醇脂肪酶 | |
JPH022362A (ja) | 新規なグルタチオン・パーオキシダーゼ遺伝子およびその用途 | |
CN105779418B (zh) | 一种新型的脂肪酶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18770777 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019507013 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018770777 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018770777 Country of ref document: EP Effective date: 20191024 |